Nicotinamide riboside alleviates cisplatin-induced peripheral neuropathy via SIRT2 activation.

ABSTRACT:

Background

Chemotherapy-induced peripheral neuropathy represents a major impairment to the quality of life of cancer patients and is one of the most common dose-limiting adverse effects of cancer treatment. Despite its prevalence, no effective treatment or prevention strategy exists. We have previously provided genetic evidence that the NAD⁺-dependent deacetylase, SIRT2, protects against cisplatin-induced peripheral neuronal cell death and neuropathy by enhancing nucleotide excision repair. In this study, we aimed to examine whether pharmacologic activation of SIRT2 would provide effective prevention and treatment of cisplatin-induced peripheral neuropathy (CIPN) without compromising tumor cell cytotoxic response to cisplatin.

Methods

Using von Frey and dynamic ho

SUBMITTER: Acklin S 

PROVIDER: S-EPMC9297957 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature